LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS

• US 20100273808A1
• Filed: 11/20/2009
• Published: 10/28/2010
• Est. Priority Date: 11/21/2008
• Status: Abandoned Application

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Boyle, Craig J.S., Armitage, Ian, Bourland, Michael E., Ferdous, Abu J., Langston, Marianne, Cooper, Martin Ian
• Application Number:
  US12/622,617
• Publication Number:
  US 20100273808A1
• Time in Patent Office: Days
• US Class Current: 514/252.170
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07D 239/94 Nitrogen atoms

Abstract

This invention provides a compound of formula (I):

or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma)glomerulosclerosis, fibrotic disease and inflammation.

Claims

1. The compound of formula (I):

2. The compound of claim 1, wherein at least 95% by weight is crystalline.

3. The compound of claim 1, wherein the crystalline form is Form 1.

4. The compound of claim 3, wherein Form 1 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 5.50°

, 10.98°

, 19.65°

, 19.97°

, and 21.83°

.

5. The compound of claim 3, wherein Form 1 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 5.50°

, 19.65°

, and 19.97°

.

6. The compound of claim 3, wherein Form 1 is characterized by at least one of the following features (I-i)-(I-iii):

(I-i) at least one of the X-ray powder diffraction peaks shown in Table 1;

(I-ii) an X-ray powder diffraction pattern substantially similar to FIG. 1; and

(I-iii) a differential scanning calorimetry (DSC) profile having an endothermic range of about 175°

C. to about 185°

C., with an onset temperature of about 177°

C.

7. The compound of claim 1, wherein the crystalline form is Form 2.

8. The compound of claim 7, wherein Form 2 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 6.38°

, 7.98°

, 11.19°

, 14.12°

, 19.39°

, 20.41°

, 20.68°

, 21.44°

, and 27.65°

.

9. The compound of claim 7, wherein Form 2 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 11.19°

, 19.39°

, 20.41°

, and 21.44°

.

10. The compound of claim 7, wherein Form 2 is characterized by at least one of the following features (II-i)-(II-iii):

(II-i) at least one of the X-ray powder diffraction peaks shown in Table 2;

(II-ii) an X-ray powder diffraction pattern substantially similar to FIG. 4; and

(II-iii) a differential scanning calorimetry (DSC) profile, comprising a first endothermic range of about 150°

C. to about 160°

C., with an onset temperature of about 155.7°

C.

11. The compound of claim 1, wherein the crystalline form is Form 3.

12. The compound of claim 11, wherein Form 3 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 3.66°

, 11.04°

, 19.93°

, and 23.98°

.

13. The compound of claim 11, wherein Form 3 is characterized by at least one of the following features, (III-i)-(III-iii):

(III-i) at least one of the X-ray powder diffraction peaks shown in Table 3;

(III-ii) an X-ray powder diffraction pattern substantially similar to FIG. 7; and

(III-iii) a differential scanning calorimetry (DSC) profile substantially similar to FIG. 8.

14. The compound of claim 1, wherein the crystalline form is Form 4.

15. The compound of claim 14, wherein Form 4 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 11.30°

, 12.71°

, 15.15°

, 16,02°

, 20.03°

, 24.15°

, and 24.66°

.

16. The compound of claim 14, wherein Form 4 is characterized by at least one X-ray powder diffraction peak at 2θ

angles of 11.30°

, 16.02°

, 20.03°

, and 24.15°

.

17. The compound of claim 14, wherein Form 4 is characterized by at least one of the following features, (IV-i)-(IV-iii):

(IV-i) at least one of the X-ray powder diffraction peaks shown in Table 4;

(IV-ii) an X-ray powder diffraction pattern substantially similar to FIG. 10; and

(IV-iii) a differential scanning calorimetry (DSC) profile substantially similar to FIG. 11.

41. A method for treating cancer, comprising the administration of a therapeutically effective amount of a compound according to claim 1, and a pharmaceutically acceptable carrier or diluent.

43. The method of claim 41 or 42, wherein the cancer is AML, or malignant glioma.

44. The method of claim 43, wherein the malignant glioma is glioblastoma multiforme.

18. A pharmaceutical composition comprising the compound of formula (I):

19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises about 30% to about 60% of the compound of formula (I), or a crystalline form thereof;

about 6% to about 12% of a lubricant;

about 6% to about 12% of a disintegrant;

about 15% to about 50% of a filler; and

about 0.3% to about 2% of a glidant, by weight as a percentage of total weight.

20. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises about 45% to about 55% of the compound of formula (I), or a crystalline form thereof;

about 9% to about 11% of a lubricant;

about 8% to about 10% of a disintegrant;

about 20% to about 40% of a filler; and

about 0.8% to about 1.5% of a glidant, by weight as a percentage of total weight.

21. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is an oral pharmaceutical dosage form.

22. The pharmaceutical composition of claim 21, wherein the oral pharmaceutical dosage form is a tablet.

23. The pharmaceutical composition of claim 18, wherein the crystalline form is Form 1.

24. The pharmaceutical composition of claim 18, wherein the compound of formula (I), or a crystalline form thereof, is present in an amount of about 30% to about 60%, by weight as a percentage of total weight.

25. The pharmaceutical composition of claim 18, wherein the compound of formula (I), or a crystalline form thereof, is present in an amount of about 44% to about 55%, by weight as a percentage of total weight.

26. The pharmaceutical composition of claim 18, wherein the lubricant is present in an amount of between about 6% to about 12%, by weight as a percentage of total weight.

27. The pharmaceutical composition of claim 18, wherein the lubricant comprises a first lubricant, and a second lubricant, wherein the first and second lubricants are independently magnesium stearate, sodium stearyl fumarate, or mixtures thereof.

28. The pharmaceutical composition of claim 27, wherein the first lubricant is sodium stearyl fumarate, and the second lubricant is sodium stearyl fumarate.

29. The pharmaceutical composition of claim 18, wherein the disintegrant is present in an amount of about 6% to about 12%, by weight as a percentage of total weight.

30. The pharmaceutical composition of claim 18, wherein the disintegrant comprises a first disintegrant, and a second disintegrant, wherein the first and second disintegrants are independently crospovidone, calcium silicate, sodium starch glycolate, or mixtures thereof.

31. The pharmaceutical composition of claim 30, wherein the first disintegrant is crospovidone, and the second disintegrant is crospovidone.

32. The pharmaceutical composition of claim 18, wherein the filler is present in an amount of about 15% to about 50%, by weight as a percentage of total weight.

33. The pharmaceutical composition of claim 18, wherein the filler is microcrystalline cellulose, silicified microcrystalline cellulose, isomalt, mannitol, or mixtures thereof.

34. The pharmaceutical composition of claim 33, wherein the filler is mannitol.

35. The pharmaceutical composition of claim 18, wherein the glidant is present in an amount of about 0.3% to about 2%, by weight as a percentage of total weight.

36. The pharmaceutical composition of claim 18, wherein the glidant is silicon dioxide, colloidal silicon dioxide, talc, tribasic calcium phosphate, starch, magnesium trisilicate, powdered cellulose, or mixtures thereof.

37. The pharmaceutical composition of claim 36, wherein the glidant is colloidal silicon dioxide.

38. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises about 45% to about 55% of the compound of formula (I) Form 1;

about 9% to about 11% of sodium stearyl fumarate;

about 8% to about 10% of crospovidone;

about 20% to about 40% of mannitol; and

about 0.8% to about 1.5% of colloidal silicon dioxide, by weight as a percentage of total weight.

42. A method for treating cancer, comprising the administration of a therapeutically effective amount of a pharmaceutical composition according to claim 18.

39. A process for the bulk production of an oral pharmaceutical dosage form of the compound of formula (I), or a crystalline form thereof, wherein the oral pharmaceutical dosage form is a tablet, comprising the steps of:

(a-1) blending the compound of formula (I), or a crystalline form thereof, and sieved first lubricant;

(a-2) blending the resulting mixture from step (a-1) with sieved first disintegrant, and sieved filler;

(a-3) sieving the resulting mixture from step (a-2), then further blending;

(a-4) roller compacting the resulting mixture from step (a-3) to a ribbon;

(a-5) milling the resulting ribbon from step (a-4);

(a-6) blending the resulting granules from step (a-5) with sieved glidant, and sieved second disintegrant;

(a-7) blending the resulting mixture from step (a-6) with sieved second lubricant;

(a-8) tableting the resulting mixture from step (a-7); and

(a-9) optionally film coating the resulting tablets from step (a-8).

40. The process of claim 39, comprising the steps of:

(b-1) blending the compound of formula (I), or a crystalline form thereof, and sieved sodium stearyl fumarate;

(b-2) blending the resulting mixture from step (b-1), with sieved crospovidone, and sieved mannitol;

(b-3) sieving the resulting mixture from step (b-2), then further blending;

(b-4) roller compacting the resulting mixture from step (b-3) to a ribbon;

(b-5) milling the resulting ribbon from step (b-4);

(b-6) blending the resulting granules from step (b-5) with sieved colloidal silicon dioxide, and sieved crospovidone;

(b-7) blending the resulting mixture from step (b-6) with sieved sodium stearyl fumarate;

(b-8) tableting the resulting mixture from step (b-7); and

(b-9) optionally film coating the resulting tablets from step (b-8).